drugset / Trial / NCT02184325

Safety and Tolerability of Kiddi® Pharmaton Fizz Effervescent Tablets in Children

NCT02184325

Phase 2 Completed 96 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

Study to evaluate the tolerability and safety of Kiddi® Pharmaton Fizz effervescent tablets, in children of 6 to 14 years, comparing a given formula with an improved one with reduced mineral content (qualitatively equivalent to the first one) and a comparator product.

Timeline

Start
1999-11
Primary completion
2000-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gefitinib Small molecule
Comparator Kiddi® Pharmaton Fizz Unknown

Indications

No indication recorded.